BioCentury
ARTICLE | Clinical News

Dalbavancin: Completed Phase III enrollment

November 5, 2012 8:00 AM UTC

Durata completed enrollment in the double-blind, double-dummy, international Phase III DISCOVER-2 trial evaluating a single 1,000 mg dose of IV dalbavancin followed by a 500 mg dose given 1 week later in about 740 patients. Patients in the comparator arm will receive IV vancomycin and have the option to switch to oral linezolid, for a total treatment duration of 10-14 days. In September, Durata completed enrollment in the double-blind, active-controlled, international Phase III DISCOVER0-1 trial (see BioCentury, Sept. 10). The company has SPAs from FDA for the trials. ...